Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 195

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD‐subgroup analyses across four randomized trials

Open access
LICHTENSTEIN, G. R., DIAMOND, R. H., WAGNER, C. L., FASANMADE, A. A., OLSON, A. D., MARANO, C. W., JOHANNS, J., LANG, Y., SANDBORN, W. J.·2009·Alimentary Pharmacology & Therapeutics

Abstract

Summary: Background Benefits and risks of concomitant immunomodulators and maintenance infliximab in inflammatory bowel disease (IBD) patients have not been adequately evaluated. Aim To assess the effect of concomitant immunomodulator and infliximab maintenance therapy using data from four prospective, randomized Phase 3 trials in IBD patients. Methods Overall, 1383 patients from ACCENT I and ACCENT II [luminal and fistulizing Crohn’s disease trials] and ACT 1 and ACT 2 [ulcerative colitis trials] were analysed. Patients were treated with placebo or infliximab 5 or 10 mg/kg at weeks 0, 2 and 6 followed by every‐8‐week maintenance therapy. Clinical response, clinical remission, fistula response, complete fistula response, infection and infusion reaction rates; serum infliximab concentrations and immunogenicity were summarized by baseline concomitant immunomodulator subgroup (use or non‐use). Results Overall, almost 40% of evaluated IBD patients received concomitant immunomodulators. Efficacy, infection, and serious infection rates were generally similar in patients who received maintenance therapy with or without concomitant immunomodulators. There were no consistent differences in serum infliximab concentrations with or without immunomodulators in patients who received scheduled maintenance therapy. Concomitant immunomodulators reduced infusion reactions and immunogenicity. Conclusion Concomitant immunomodulators did not improve efficacy or pharmacokinetics in IBD patients who received maintenance infliximab.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2036.2009.04027.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 195

Metadata

Authors
LICHTENSTEIN, G. R., DIAMOND, R. H., WAGNER, C. L., FASANMADE, A. A., OLSON, A. D., MARANO, C. W., JOHANNS, J., LANG, Y., & SANDBORN, W. J.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2009-07-10
Volume
30
Issue
3
Pages
210-226
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W2056596058
Cited by
195
References
1
FWCI
12.12
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD‐subgroup analyses across four randomized trials. https://app.cochat.ai/papers/10.1111/j.1365-2036.2009.04027.x
The paper
LICHTENSTEIN, G. R., DIAMOND, R. H., WAGNER, C. L., FASANMADE, A. A., OLSON, A. D., MARANO, C. W., JOHANNS, J., LANG, Y., & SANDBORN, W. J. (2009). Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD‐subgroup analyses across four randomized trials. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2009.04027.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.